Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

Also called NCT01704261

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 307 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01704261
  • EudraCT 2012-002612-10
Main results
  • A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin BMC endocrine disorders, 2017-11-06 DOI, PubMed 29110647, PMC5674832 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01704261. Randomized; triple masking; primary purpose treatment. Start 2012-10-18 (actual); primary completion 2014-12-23 (actual). Results posted on 2015-11-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Matching placebo to Omarigliptin
Intervention (Drug)
Glimepiride
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01704261
Content hash
4190608a62f44420df16badd282f186c3dffd3f97d106db7c881545ff572b5f3